



EY Entrepreneur of the year-2013



FROST & SULLIVAN
Best Practices-2013



Business today/YES bank
Excellence Awards-2013



Date: 30th May, 2022

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: DISCLOSURES OF RELATED PARTY TRANSACTIONS UNDER REGULATION 23(9) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015, AS AMENDED (“SEBI LISTING REGULATIONS”)

Dear Sir/Madam,

Pursuant to Regulation 23(9) of the SEBI Listing Regulations, please find enclosed herewith disclosures of related party transactions on consolidated basis in the revised format, as prescribed by SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated 22 November 2021, for the half-year ended commencing from 1 October 2021 to 31 March 2022.

Kindly take note the same.

Thanking you,

Yours sincerely

For Eris Lifesciences Limited



Milind Talegaonkar
Company Secretary and Compliance Officer
Mem. No. A26493

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867

										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.									
S. No.	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty		Type of related party transaction (see Note 5)	Value of the related party transaction as approved by the audit committee (see Note 6a)	Value of transaction during the reporting period (see Note 6b)	In case monies are due to either party as a result of the transaction (see Note 1)		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments						
	Name	Name	Relationship of the counterparty with the listed entity or its subsidiary				Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Cost (see Note 7)	Tenure	Nature (loan/ advance/ inter-corporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)			
	Eris Lifesciences Limited	AMIT BAKSHI	Managing Director		Short term employee benefits		24.39	2.53	2.57										
	Eris Lifesciences Limited	INDERJEET SINGH NEGI	Director		Short term employee benefits		6.2	0.71	0.73										
	Eris Lifesciences Limited	KAUSHAL SHAH	Director		Short term employee benefits		3.5	0.43	0.46										
	Eris Lifesciences Limited	KRISHNAKUMAR VAIDYANATHAN	Director		Short term employee benefits		20.65	2.05	2.05										
	Eris Lifesciences Limited	Sachin Shah	Chief Financial Officer		Short term employee benefits		7.17	0.61	0.61										
	Eris Lifesciences Limited	Milind Talegaonkar	Company Secretary		Short term employee benefits		1.82	0.22	0.24										
	Eris Lifesciences Limited	RAJEEV NAROTAM DALAL	Independent director		Commission and Sitting fees		1.73	0	0										
	Eris Lifesciences Limited	VIJAYA SAMPATH	Independent director		Commission and Sitting fees		1.8	0	3										
	Eris Lifesciences Limited	KALPANA VASANTRAI UNADKAT	Independent director		Commission and Sitting fees		2.2	0	3.5										
	Eris Lifesciences Limited	PRASHANT GUPTA	Independent director		Commission and Sitting fees		1.8	0	2.98										
	Eris Lifesciences Limited	Parv Bakshi	Relative of KMP		Short term employee benefits		0.28		0.03										
	Eris Lifesciences Limited	Tresna foundation	CSR Expenditure		Commission and Sitting fees		2.10		0.00										
	Eris Lifesciences Limited	AMIT BAKSHI	Managing Director		Reimbursement		0.18												
	Eris Lifesciences Limited	INDERJEET SINGH NEGI	Director		Reimbursement		0.18												
	Eris Lifesciences Limited	KAUSHAL SHAH	Director		Reimbursement		0.18												
	Eris Lifesciences Limited	KRISHNAKUMAR VAIDYANATHAN	Director		Reimbursement		0.19												
	Eris Lifesciences Limited	Sachin Shah	Chief Financial Officer		Reimbursement		0.18												
	Eris Lifesciences Limited	Milind Talegaonkar	Company Secretary		Reimbursement		0.18												
	Eris Lifesciences Limited	Tresna Foundation	Relative of KMP		Corporate Social Responsibility		2.10												
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Royalty Expense	0.85													
	Eris Lifesciences Limited	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Subsidiary		Royalty Expense	0.19													
	Eris Lifesciences Limited	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Subsidiary		Royalty Expense	1													
	Eris Lifesciences Limited	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Subsidiary		Royalty Income	2.21													
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Royalty Income	2.28													
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Healthcare Private Limited	Group company		Royalty Income	0.25													
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Healthcare Private Limited	Group company		Royalty Income	0.16													
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Interest income	14.49													
	Eris Lifesciences Limited	Eris Therapeutics Limited	Subsidiary		Interest income	5.57													
	Eris Lifesciences Limited	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Subsidiary		Interest income	0.25													
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Healthcare Private Limited	Group company		Interest income	1.56													
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Therapeutics Limited	Group company		Interest income	0.2													
	Eris Healthcare Private Limited	ERIS PHARMACEUTICALS PRIVATE LIMITED	Subsidiary		Interest income	0.01													
	Eris Healthcare Private Limited	Eris Lifesciences Limited	Holding company		Sale	26.07													
	Eris Healthcare Private Limited	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Group company		Sale	0													
	Eris Healthcare Private Limited	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Group company		Sale	1.42													
	Eris Lifesciences Limited	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Subsidiary		Sale	26.41													
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Sale	48.5													
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Lifesciences Limited	Holding company		Sale	0													
	Eris Lifesciences Limited	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Subsidiary		Composit support service income	0.03													
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Composit support service income	0.3													
	Eris Lifesciences Limited	Eris Therapeutics Limited	Subsidiary		Composit support service income	0.06													
	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Group company		Sale of brand	3.8													
	Eris Lifesciences Limited	Eris Therapeutics Limited	Subsidiary		Loan given	393.5					Loan	8%	On demand	Unsecured	For business				
	Eris Lifesciences Limited	Eris Therapeutics Limited	Subsidiary		Loan received back	393.5													
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Loan given	55					Loan	8%	On demand	Unsecured	For business				
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Loan received back	151.96													
	Eris Lifesciences Limited	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Subsidiary		Loan given	46.18					Loan	8%	On demand	Unsecured	For business				
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Therapeutics Limited	Group company		Loan given	0					Loan	8%	On demand	Unsecured	For business				
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Therapeutics Limited	Group company		Loan received back	10													
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Healthcare Private Limited	Group company		Loan given	110					Loan	8%	On demand	Unsecured	For business				
	Eris Lifesciences Limited	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Subsidiary		Trade receivable		0	0.82											
	Eris Lifesciences Limited	Eris Therapeutics Limited	Subsidiary		Trade receivable		0	0.06											
	Eris Lifesciences Limited	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Subsidiary		Trade receivable		1.3	0											
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Trade receivable		6.27	0											
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Group company		Trade receivable		0.82	0.8											
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Healthcare Private Limited	Group company		Trade receivable		0.53	0											
	Eris Healthcare Private Limited	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Group company		Trade payable		0.53	0											
	Eris Lifesciences Limited	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Subsidiary		Trade payable		1.75	0											
	Eris Lifesciences Limited	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Subsidiary		Trade payable		0.38	0											
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Trade payable		1.75	0											
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Healthcare Private Limited	Group company		Trade payable		0.16	0											
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Advances to creditor		0	3.35											
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Lifesciences Limited	Holding company		Advances to creditor		0	3.81											
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Group company		Other current assets		0	9.08											
	Eris Lifesciences Limited	Eris Healthcare Private Limited	Subsidiary		Loan given balance		361.81	264.85											
	Eris Lifesciences Limited	Eris M J Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited)	Subsidiary		Loan given balance		0	46.41											
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Healthcare Private Limited	Group company		Loan given balance		20.73	132.14											
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Therapeutics Limited	Group company		Loan given balance		10.01	0											
	Eris Healthcare Private Limited	ERIS PHARMACEUTICALS PRIVATE LIMITED	Subsidiary		Loan given balance		0.1	0.11											
	Eris Lifesciences Limited	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Subsidiary		Perpetual bond investment		200	200											
	Aprica Healthcare Limited (Formerly known as UTH Healthcare Limited)	Eris Healthcare Private Limited	Group company		Perpetual bond investment		30	30											

Notes:

1. The details in this format are required to be provided for all transactions undertaken during the reporting period. However, opening and closing balances, including commitments, to be disclosed for existing related party transactions even if there is no new related party transaction during the reporting period.

2. Where a transaction is undertaken between members of the consolidated entity (between the listed entity and its subsidiary or between subsidiaries), it may be reported once.

3. Listed banks shall not be required to provide the disclosures with respect to related party transactions involving loans, inter-corporate deposits, advances or investments made or given by the listed banks.

4. For companies with financial year ending March 31, this information has to be provided for six months ended September 30 and six months ended March 31. Companies with financial years ending in other months, the six months period shall apply accordingly.

5. Each type of related party transaction (for e.g. sale of goods/services, purchase of goods/services or whether it involves a loan, inter-corporate deposit, advance or investment) with a single party shall be disclosed separately and there should be no clubbing or netting of transactions of same type. However, transactions with the same counterparty of the same type may be aggregated for the reporting period. For instance, sale transactions with the same party may be aggregated for the reporting period and purchase transactions may also be disclosed in a similar manner. There should be no netting off for sale and purchase transactions. Similarly, loans advanced to and received from the same counterparty should be disclosed separately, without any netting off.

6. In case of a multi-year related party transaction:

a. The aggregate value of such related party transaction as approved by the audit committee shall be disclosed in the column "Value of the related party transaction as approved by the audit committee".

b. The value of the related party transaction undertaken in the reporting period shall be reported in the column "Value of related party transaction during the reporting period".

7. "Cost" refers to the cost of borrowed funds for the listed entity.

8. PAN will not be displayed on the website of the Stock Exchange(s).

9. Transactions such as acceptance of fixed deposits by banks/NBFCs, undertaken with related parties, at the terms uniformly applicable offered to all shareholders/ public shall also be reported.